Phaseline

Targets › CLDN1

CLDN1 (Claudin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2027.

Claudins function as major constituents of the tight junction complexes that regulate the permeability of epithelia. While some claudin family members play essential roles in the formation of impermeable barriers, others mediate the permeability to ions and small molecules. (UniProt, O95832)

Open in Phaseline: the race on CLDN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alentis TherapeuticsALE.F02
anti-CLDN1 monoclonal antibody targeting non-tight junction exposed form
CLDN1Phase 2Glomerulonephritis Rapidly ProgressiveJun 2027

Conditions

Glomerulonephritis Rapidly Progressive (1)

Modalities

mixed (1)

Companies

Alentis Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.